Bibliographic citations
Villanueva, M., (2024). Efecto de la budesonida combinada con montelukast sódico sobre la eficacia clínica y función pulmonar en niños con asma bronquial: una Revisión sistemática y metaanálisis [Tesis, Universidad Privada Antenor Orrego]. https://hdl.handle.net/20.500.12759/48011
Villanueva, M., Efecto de la budesonida combinada con montelukast sódico sobre la eficacia clínica y función pulmonar en niños con asma bronquial: una Revisión sistemática y metaanálisis [Tesis]. PE: Universidad Privada Antenor Orrego; 2024. https://hdl.handle.net/20.500.12759/48011
@phdthesis{renati/1357583,
title = "Efecto de la budesonida combinada con montelukast sódico sobre la eficacia clínica y función pulmonar en niños con asma bronquial: una Revisión sistemática y metaanálisis",
author = "Villanueva Díaz, María Ysabel",
publisher = "Universidad Privada Antenor Orrego",
year = "2024"
}
To evaluate the effect of the combination of budesonide and montelukast sodium on clinical efficacy and lung function in children with bronchial asthma. Methods: Randomized controlled clinical trials were included as results of the literature search in Pubmed, Scopus, Ovid/Medline, Embase, Web of Science, and Cochrane Central databases. The combination of budesonide and montelukast sodium was presented as the intervention group and the combination of budesonide and placebo as the control group. RevMan 5.3 software was used for quality assessment and meta-analysis of the articles. Results: Two clinical trials involving a total of 55 children in the intervention group and 55 children in the control group were included. Uncertain results were found on the improvement of clinical efficacy and lung function in the intervention group compared to the control group. FEV1, as a lung outcome measure, showed a statistically nonsignificant difference between the two groups, with an effect size of SMD = 1.20 (95%CI: 0.78~1.61, P = 0.10). In terms of the risk of bias assessment, the studies had a low risk of bias. Conclusion: The results of the combination of budesonide and montelukast sodium, compared with the combination of budesonide and placebo, are uncertain in terms of improving clinical efficacy and lung function in children with bronchial asthma. However, further clinical trials are required to adequately evaluate the existing evidence.
This item is licensed under a Creative Commons License